



CIRB Approval of Recruitment/Patient Education Materials

Date: February 2, 2021

Study ID: S1914

Study Title: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

Study Chair: Megan Daly MD

The NCI Adult CIRB - Late Phase Emphasis reviewed S1914 Recruitment Materials (dated 01/28/21) on January 29, 2021 and granted approval. The expedited review was conducted in accordance with the Federally-defined categories of expedited review stated in 45 CFR 46.110(b)(1)(ii) and 21 CFR 56.110(b)(2).

The following documents were reviewed:

1. CIRB Application (PVD 04/13/20)
2. Plain Language Summary
3. Tweets and Graphics

As the Study Chair, you are responsible for reporting all study-related activity and correspondence to the CIRB.

The CIRB complies with the Federal regulations 45 CFR 46, 21 CFR 50, and 21 CFR 56.

If you have any questions regarding this review, please contact the Adult CIRB - Late Phase Emphasis Coordinator at adultcirb@emmes.com.

cc: Gretchen Goetz, M.B.A.
Dana Sparks